Saroja Pharma Industries India (NSE:SAROJA) Notes Receivable: ₹0.0 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAROJA Saroja Pharma Industries India Ltd NSE:SAROJA
15 GF Score
Price ₹40.95
! 4 Warning Signs
View Full Analysis

What is Saroja Pharma Industries India Notes Receivable?

Saroja Pharma Industries India NSE:SAROJA +3.15% 15 Notes Receivable is ₹0.0 Mil as of Mar. 2025. GuruFocus rates NSE:SAROJA with a GF Score™ of 15/100. The stock has 4 warning signs investors should review.

Saroja Pharma Industries India's Notes Receivable for the quarter that ended in Mar. 2025 was ₹0.0 Mil.

Saroja Pharma Industries India Notes Receivable Related Terms

Saroja Pharma Industries India Notes Receivable Historical Data

* Premium members only.

The historical data trend for Saroja Pharma Industries India's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Saroja Pharma Industries India Notes Receivable Chart

Saroja Pharma Industries India Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Notes Receivable
0.00 0.00 0.00 0.00 0.00

Saroja Pharma Industries India Semi-Annual Data
Mar21 Mar22 Mar23 Mar24 Mar25
Notes Receivable 0.00 0.00 0.00 0.00 0.00
NSE:SAROJA
15GF Score
Saroja Pharma Industries India Ltd NSE:SAROJA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Saroja Pharma Industries India Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0.0 Mil mean?
Saroja Pharma Industries India (NSE:SAROJA) has a Notes Receivable of ₹0.0 Mil as of Mar. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Saroja Pharma Industries India and its competitors.
Is Saroja Pharma Industries India's Notes Receivable too high?
Saroja Pharma Industries India's current Notes Receivable is ₹0.0 Mil. Overall, Saroja Pharma Industries India has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Saroja Pharma Industries India's Notes Receivable compare to ZTS?
Saroja Pharma Industries India's Notes Receivable of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Saroja Pharma Industries India and its competitors. Saroja Pharma Industries India's current Notes Receivable is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saroja Pharma Industries India stock overvalued right now?
Saroja Pharma Industries India (NSE:SAROJA) has a current Notes Receivable of ₹0.0 Mil. The current Notes Receivable is ₹0.0 Mil. Saroja Pharma Industries India's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Saroja Pharma Industries India (NSE:SAROJA), the current Notes Receivable is ₹0.0 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Saroja Pharma Industries India Business Description

Address Jata Shankar Dosa Marg, Shop No. 209, 2ND Floor, Ecstacy, City of Joy, Mulund west, Mumbai, MH, IND, 400080
Saroja Pharma Industries India Ltd is a company engaged in the pharmaceutical and healthcare sector. The company trades in pharmaceutical active pharmaceutical ingredients, pharma intermediates, chemicals, and solvents used for pharmaceutical products, including human and veterinary medicines. The company has only one reportable business segment, which is pharma chemicals, such as thionyl chloride and pharmaceutical intermediates. Geographically, it operates in India, Asia Pacific, Europe, and other regions, with the majority of its revenue generated from India.
15GF Score

Get the complete analysis for NSE:SAROJA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹40.95
Price